Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
For Investors +
Join Us

Press Releases

Year

December 3, 2024

Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis

November 12, 2024

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update

October 29, 2024

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

October 28, 2024

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 18, 2024

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

September 10, 2024

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 9, 2024

Roivant Provides Update on Graves’ Disease Development Program

August 8, 2024

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

July 25, 2024

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

May 30, 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 14

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2025 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn